Best treatment choices for newborns with suspected early infection
Part of Genetic & congenital, Infections clinical trials.
This trial is testing ways to make the best treatment decisions for newborns who may have an early infection (sepsis). It focuses on babies born at 34 weeks or later and within their first three days of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is born at 34 weeks of pregnancy or later
- Your baby is between 0 and 3 days old
- Your baby is alive (not stillborn)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a blood test (presepsin) can help doctors safely stop antibiotics earlier in preterm babies at moderate risk of infection. The goal is to reduce unnecessary antibiotic use.
This trial tests a new, faster way to find bacteria in the blood of children with suspected sepsis. It uses a molecular test that may give results sooner than standard cultures, helping doctors treat infections more quickly.
This study aims to find new ways to quickly diagnose sepsis (a severe response to infection) in patients arriving at the emergency room. If successful, these new tests could help doctors start treatment faster.
This study is testing a new blood test to see if it can help doctors decide when to use antibiotics for newborns who may have a late-onset infection. The goal is to reduce unnecessary antibiotic use.
This trial tests whether a new calculator helps doctors decide the best care for newborns at risk of early infection. It looks at babies born at 35 weeks or later who had a blood test for infection.
This study is testing a new blood test (called presepsin) to see if it can help doctors quickly diagnose sepsis (a serious infection) in newborns. If your baby has signs of infection, this test might help find the cause sooner.
Hear when a new Early Onset Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.